Repare TherapeuticsRPTX
Market Cap: $149M
About: Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
Employees: 179
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
33% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]
11% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 18
5.28% less ownership
Funds ownership: 84.87% [Q1] → 79.59% (-5.28%) [Q2]
14% less funds holding
Funds holding: 71 [Q1] → 61 (-10) [Q2]
34% less capital invested
Capital invested by funds: $169M [Q1] → $112M (-$57M) [Q2]
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
73% less call options, than puts
Call options by funds: $19K | Put options by funds: $70K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Robert Burns 45% 1-year accuracy 61 / 135 met price target | 186%upside $10 | Buy Reiterated | 4 Sept 2024 |
Financial journalist opinion
Based on 4 articles about RPTX published over the past 30 days